Next Article in Journal
Influence of Iron on Bone Homeostasis
Next Article in Special Issue
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Previous Article in Journal
Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis
Previous Article in Special Issue
Molecular Application of Aptamers in the Diagnosis and Treatment of Cancer and Communicable Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 11
Issue 4
10.3390/ph11040106
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging

by
Leila Hassanzadeh
1,2,
Suxiang Chen
2,3 and
Rakesh N. Veedu
2,3,*
1
Department of Nuclear Medicine, School of Medicine, Rajaie Cardiovascular, Medical and Research Center & Department of Medicinal Chemistry, School of Pharmacy-International Campus, Iran University of Medical Sciences, Tehran 1449614535, Iran
2
Centre for Comparative Genomics, Murdoch University, Perth 6150, Australia
3
Perron Institute for Neurological and Translational Science, Perth 6009, Australia
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2018, 11(4), 106; https://doi.org/10.3390/ph11040106
Submission received: 22 August 2018 / Revised: 6 October 2018 / Accepted: 10 October 2018 / Published: 15 October 2018
(This article belongs to the Special Issue Aptamer-Based Diagnostics and Therapeutics)
Browse Figures
Versions Notes

Abstract

:
Aptamers are short single-stranded DNA or RNA oligonucleotide ligand molecules with a unique three-dimensional shape, capable of binding to a defined molecular target with high affinity and specificity. Since their discovery, aptamers have been developed for various applications, including molecular imaging, particularly nuclear imaging that holds the highest potential for the clinical translation of aptamer-based molecular imaging probes. Their easy laboratory production without any batch-to-batch variations, their high stability, their small size with no immunogenicity and toxicity, and their flexibility to incorporate various functionalities without compromising the target binding affinity and specificity make aptamers an attractive class of targeted-imaging agents. Aptamer technology has been utilized in nuclear medicine imaging techniques, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET), as highly sensitive and accurate biomedical imaging modalities towards clinical diagnostic applications. However, for aptamer-targeted PET and SPECT imaging, conjugation of appropriate radionuclides to aptamers is crucial. This review summarizes various strategies to link the radionuclides to chemically modified aptamers to accomplish aptamer-targeted PET and SPECT imaging.

1. Introduction

Molecular imaging technologies employ labeled molecules to explore biological targets in living subjects for disease detection and monitoring treatment progress in real time. The nuclear imaging technique is a powerful approach to achieve highly sensitive imaging. The two most current approaches, that is, positron emission tomography and single photon emission computed tomography, use radionuclides to label specific therapeutic and/or diagnostic (theranostic) molecules for diagnosis and prognosis of many diseases [1,2]. Clinical molecular imaging using these techniques facilitates characterization of biological processes in vivo on a molecular and cellular level [3]. In modern nuclear medicine, approximately 95% of radiopharmaceuticals are used for diagnostic purposes [4]. In addition to small chemical structures, radiopharmaceuticals may consist of bigger biomolecules, such as antibodies, antibody fragments, proteins, peptides, and nucleic acids that are usually more specific [5].
Aptamers are oligomers composed of deoxyribonucleotides (DNA aptamers) or ribonucleotides (RNA aptamers), which are promising targeting biomolecules in nuclear medicine. Various three-dimensional structures of aptamers via intramolecular interactions, such as hydrogen bonds, hydrophobic effects, Vander Waals forces, and so on, enable them to bind the target binding domain (aptatope) [6]. Aptamers are able to bind different types of targets, such as small ions like Zn2+, large targets like proteins, whole cells, bacteria, or viruses [7,8,9,10]. These structures can easily differentiate between closely similar molecules, such as the presence or absence of a hydroxyl or methyl group, a urea against a guanidine group, and d or l amino acids that make them highly specific compounds [11,12,13,14]. Their high specificity, easy solid phase chemical synthesis, and small size for high tissue penetration make aptamers excellent alternate molecules for use in the medical, pharmaceutical, and biotechnological fields [15]. In this review, we focus on various methods of radiolabeling that have been performed using aptamers and other potential approaches to producing diagnostic tracers in SPECT and PET imaging techniques (Figure 1).

2. Improving the Stability of Aptamers

Nucleic acid aptamers composed of natural nucleotide monomers show very low resistance to nucleases and are rapidly degraded in vivo. To overcome this significant limitation, chemically-modified nucleotide analogues (Figure 2) are generally systematically incorporated to a developed DNA or RNA aptamer without compromising the target binding affinity and specificity [16]. Some of the prominent modified nucleotides which have been explored in aptamer fabrication are shown in Figure 2. Recently, Lipi et al. provided an in-depth review on developing chemically-modified aptamers [17]. Often termed as ‘chemical antibodies’, aptamers are ideal alternative molecules to antibodies for targeted molecular imaging applications, and several researchers utilized the potential of aptamers in nuclear medicine [18]. Different factors influence the in-vivo half-life of the radiolabeled aptamers and alter the biodistribution patterns and clearance pathways, which greatly influence imaging efficiency. Fast clearance of imaging probes might be an advantage because of high target to background ratio. Incorporation of chemically-modified nucleotides certainly improves the properties of aptamers as targeted imaging probes; however, improved nuclease resistance and stability could also enhance the retention time of aptamers and target binding in the body [19].

3. SPECT and PET Imaging Techniques

Based on the type of radionuclides used, two types of imaging techniques are employed in nuclear medicine, (1) SPECT (single-photon emission computed tomography), which employs γ-emitting radionuclides, including 99mTc, 123I, 67Ga, and 111In, and (2) PET (positron emission tomography), which uses β+-emitting radionuclides, including 18F, 11C, 13N, 15O, 68Ga, 82Rb, 64Cu, and 89Zr [4]. Table 1 shows the properties of prominent radionuclides, all of which are diagnostic radionuclides and emit a positron or gamma photon. Each radionuclide has a specific physical half-life, decay mode, chemical properties, and a production method. The physical half-life and decay mode is characteristic for a given radionuclide and not aligned with any physicochemical condition and cannot be changed with any other method, such as a physicochemical modification. Therefore, it is important to consider the characteristics of radionuclides to target the biological process or disease, which is to be visualized, characterized, or measured [20].

4. Radiolabeling of Ligands for SPECT Imaging

4.1. 99mTc-Radiolabeling

Currently, in most diagnostic nuclear medicine procedures 99mTc is used because of its desirable physical characteristics (half-life: 6.02 h; energy: 140.51 keV and pure gamma emission). Additionally, technetium-99m is readily available in a sterile, pyrogen-free and carrier-free state from 99Mo/99mTc generators. On the other hand, radiolabeling of aptamers in most situations is a challenging process that needs further chemical synthesis in order to conjugate aptamers to chelating agents, such as Mercaptoacetyltriglycine (MAG3), Diethylenetriaminepentaacetic acid (DTPA), Hydrazinonicotinamide (HYNIC), and Tetraazacyclododecane tetraacetic acid (DOTA), which have the capability for radioisotopes to be attached to them [21,22]. There are two different methods of 99mTc-labeling for aptamers: (1) Direct method; (2) Indirect method.

4.1.1. Direct 99mTc/188Re Radiolabeling of Aptamers

In this method of radiolabeling, 99mTc without any chelating agent attaches to the biomolecule. It seems to be more favorable because of easy and rapid preparation, less cost and manipulation, and reduction of probable degradation. In 2014, for the first time, the direct 99mTc-labeling of aptamers was reported by Correa C.R. et al. [23]. Two aptamers, with and without primary amine group, were selected and radiolabeled with 99mTcO4− in the presence of stannous chloride as a reducing agent. The reduction of 99mTc from 7+ oxidation state to a lower oxidation state is required to stimulate a chemical reaction of the 99mTc to many compounds [4]. The aforementioned aptamers were directly labeled with 99mTc by addition of an aliquot of Na99mTcO4 in the sealed vial, containing Ethylenediamine-N,N′-diacetic acid (EDDA) and tricine. Both aptamers’ radiolabeling showed high radiochemical efficiencies and considerable in vitro stability [23]. The next direct radiolabeling of aptamers was performed on several unmodified aptamers with an amine-ended linker by Cao et al. in 2015, and on (1→3)-β-D-glucan aptamers by de Sousa Lacerda et al. in 2017 [24,25]. Radiochemical purities that were reported by TLC (thin layer chromatography) indicated high radiolabeling efficiency. Direct radiolabeling of aptamers with Rhenium (188Re) was reported to radiolabel a DNA aptamer to target EGFRvIII for glioblastoma diagnoses by Xidong Wu et al. in 2014. In this method, an aptamer was dissolved in acetic acid (pH 5.0) and radiolabeling was performed in the presence of SnCl2 and ascorbic acid, followed by the addition of 188Re eluent and warming at 37 °C for 1.5 h [26].

4.1.2. Indirect 99mTc-Labeling of Aptamers

The labeling of oligomers is performed using a similar strategy to that employed for other biologicals, such as antibodies and peptides. Since 99mTc is an isotope of a metal, the chelator molecule needs to be attached via a linker to avoid steric hindrances [27]. The 99mTc species in a lower oxidation state react chemically with a different type of chelating agents. The chelating agent usually donates lone pairs of electrons to reduced 99mTc to generate coordinate covalent bonds [4]. The application of bifunctional chelators such as MAG3, DTPA, and DOTA for radiolabeling oligonucleotides with some radionuclides is described below [27].
Mercaptuacetyltriglycine (MAG3) derivatives: One of the attractive 99mTc-chelators for labeling biomolecules is MAG3 that forms stable radioligands in vivo and in vitro without any coligand requirements [28]. Prior to radiolabeling, the tetradentate mercapto–acetyltriglycine is used as its benzyl or benzoyl protected derivative (S-benzoyl or benzyl MAG3) to avoid the formation of considerable amounts of disulphide-bond, which is removed by heating at 100 °C for 10 min during 99mTc-labeling (Figure 3) [29,30]. Rapid deprotection requires higher temperature and alkaline pH [31].
To avoid the tough conditions of alkaline pH and boiled water temperature of benzoyl deprotection, N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycinate (NHS–MAG3) was synthesized, in which an acetyl group substituted the benzoyl group. Acetyl as a better leaving group, can be removed at room temperature and neutral pH more easily [32]. The developed MAG3 bifunctional chelator (S-acetyl NHS–MAG3) was used for 99mTc-radiolabeling of aptamers and amine derivatized oligonucleotides (Figure 4) [27].
However, in line with previous reports, postlabeling purification was required to increase the radiochemical purity to 90% or higher, while the labeling of DNAs was performed with 99mTc at neutral pH and room temperature [31,33,34,35]. But, Wang et al. reported the radiolabeling procedure of a 16-mer oligonucleotide with a primary amine group at 5′-end and NHS–MAG3 as a bifunctional chelating agent without any purification requirements after labeling [28]. Using NHS–MAG3 as bifunctional chelating agents for 99mTc radiolabeling of different types of oligonucleotides has been reported in various studies [28,36,37,38,39]. The synthesis of NHS–MAG3 could be readily conducted according to the procedure described by Winnard et al. [31] or by reacting S–acetylmercaptoacetyltriglycine with N–hydroxysuccinimide in the presence of N,N′–dicyclohexylcarbodiimide (DCC) as a dehydration reagent in anhydrous N–methyl-2–pyrrolidinone (NMP). The conjugation procedure of biomolecule to NHS–MAG3 and 99mTc-radiolabeling is reported in detail by Wang et al. [28]. A truncated modified RNA aptamer with high affinity for the human matrix metalloprotease 9 (hMMP-9), has been functionalized by conjugating its 5′-end with S–acetylmercaptoacetyltriglycine (MAG3) through a hexylamino linker. It was then radiolabeled with 99mTc and successfully employed for the detection of hMMP-9 (the tumor biomarker) in human glioblastoma sections (in vitro) and in mice bearing human melanoma tumors (in vivo) [40,41].
Diethylenetriaminepentaacetic acid (DTPA): The unshared pair of electrons in the molecules containing NH3, −CN, −SH, −COO, −NH2, and CO can be donated to a metal ion to form a complex. Diethylenetriaminepentaacetic acid (DTPA) and Ethylenediaminetetraacetic acid (EDTA) are usual examples of such chelating agents, with oxygen in carboxyl groups and nitrogen in the amino groups as donor atoms. DTPA has previously been used for radiolabeling antibodies with 99mTc, but the resulting radiolabeled ligand was considerably unstable [42]. A covalent coupling method of DTPA to proteins using bicyclic anhydride of DTPA has been reported [43], which was prepared by a one-step synthesis according to the method of Eckelman et al. [44]. The product, when protected from moisture, was stable for many months at room temperature, and the cyclic nature of DTPA anhydride produced by the suggested method above was confirmed by the characteristic evaluation [43]. The cyclic anhydride DTPA has been widely used [43] to radiolabel amine derivatized oligonucleotides with 99mTc (Figure 5) [35,45]. An extra amount of anhydride is usually necessary to compensate the hydrolysis of the anhydride that will occur in an aqueous solution in competition with conjugation. DTPA conjugation to DNAs according to the abovementioned method was reported by Hnatowich et al. in 1995 [46].
Hydrazinonicotinamide (HYNIC): One of the most useful bifuctional chelating agents used in 99mTc-labeling of biomolecules is HYNIC (6-hydrazinopyridine-3-carboxylic acid or hydrazinonicotinamide). The active ester of HYNIC is used to conjugate with the biomolecule—for example, the amino groups of lysine residues in proteins, peptides, or amine-labeled oligonucleotides. HYNIC is able to occupy just two sites of the technetium coordination sphere; coligands such as tricine, EDTA, trisodium triphenylphosphinetrisulfonate (TPPTS) are used to bind other sites and enhance the labeling yield [4]. In 2017, Calzada et al. published a HYNIC-conjugated aptamer radiolabeled with 99mTc. A shortened sequence of the original aptamer Sgc8, which has showed similar binding properties to protein kinase 7 membrane receptor, was modified at the 5′-end with an aminohexyl−moiety (Sgc8−C6−NH2) that could be reacted with the bifunctional agent 6-hydrazinonicotinamide succinimidyl ester (Suc−HYNIC) (Figure 6). To synthesize a HYNIC conjugated aptamer, excess amount of Suc−HYNIC (in dry DMSO) was added to an aqueous solution of Sgc8−C6−NH2. After purification and chemical characterization, 99mTcO4− was used for radiolabeling the HYNIC chelator by incubating with SnCl2 and tricine [47]. Another HYNIC conjugation was reported for the AS1411 aptamer targeting nucleolin protein (dissolved in a borate buffer) using NHS−HYNIC (in dried dimethylformamide). A purified HYNIC aptamer was dissolved in ammonium acetate and radiolabeled by adding 99mTc–pertechnetate solution in the presence of SnCl2.2H2O as the reducing agent and tricine as a coligand [48].
1,4,7,10-Tetraazacyclododecane or 1,4,7,10-tetraacetic acid or Tetraxetan (DOTA): DOTA, a macrocyclic bifunctional chelating agent, binds to trivalent metals such as Indium (In3+), Yttrium (Y3+), and other metals of lanthanide series rapidly under mild conditions that enable high radiolabeling efficiencies to be achieved at room temperature in comparison with acyclic ligands, such as DTPA. It can be readily modified into a bifunctional chelating agent by the derivatization of one of the carboxylates [49]. Macrocyclic complexes are often extremely resistant to dissociation (macrocyclic effect) because the structures are rather rigid and a great deal of strain in the ligand may need to be overcome in order to break the first metal–donor bond [50]. In 2012, Ren et al. reported the 99mTc radiolabeling of hTERT (human tumor telomerase reverse transcriptase) antisense oligonucleotide (ASON) through the bifunctional chelator DOTA. The ASON sequence, 5′-TAG AGA CGT GGC TCT TGA-3′, was conjugated with DOTA–NHS via the amine-functionalization of the oligonucleotides at the 3′-end [51]. DOTA–NHS–ester was prepared using the published procedure [52,53]. In brief, DOTA, 1-(3-Dimethylaminoptoply)-3-ethylcarbodimide hydrochloride (EDC–HCl) and N–hydroxysulfo–succinimide sodium S–NHS were added in PBS (Phosphate Buffered Saline) (pH 5.5). Then, the semistable amino-reactive intermediate DOTA–NHS–ester was added to ASON and radiolabeled by 99mTcO4− with SnCl2 at room temperature (Figure 7). The reported radiochemical purity was 85% [51]. Calzada et al. successfully linked both 99mTc and 67Ga to an aptamer (Sgc8) through the HYNIC and DOTA chelators, which showed desirable biodistribution and pharmacokinetic properties [47]. In 2018, Dr. Hugo Cerecetto et al. reported the synthetic efforts to prepare conjugates between Sgc8-c (a truncated sequence of the original aptamer Sgc8) and different metallic ion chelator moieties, such as HYNIC, DOTA, and NOTA (1,4,7-triazacyclononane–N,N′,N′′–triacetic acid), were covalently attached at the 5′-end of the aptamer, and were found to be stable in an aqueous solution up to 75 °C for 30 days [54].

5. Radiolabeling of Ligands for PET Imaging

PET imaging is a sensitive, noninvasive nuclear medicine imaging technique. This technique is able to measure biomedical, pharmacological, and metabolic processes quantitatively in vivo. Consequently, labeling of oligonucleotide with PET radionuclides is a versatile tool to assess the in vivo behavior. Commonly used PET radionuclides are 15O, 13N, 11C, and 18F, with 2.07, 9.97, 20.3, and 110 min half-life, respectively, out of which 18F has a more favorable half-life [55,56]. Other positron emitting radionuclides are 64Cu, 89Zr, and, most importantly, 68Ga, which is easily available via a Germanium-68/Gallium-68 Generator in nuclear medicine centers.

5.1. 18F Radiolabeling

5.1.1. ([18F]fluoromethyl)phenyl Isothiocyanate

The possibility of incorporating 18F into oligonucleotide was reported by Hedberg and Längström in 1997. They developed a one-step synthesis of a labeled compound containing the isothiocyanate functionality ([18F]fluoromethyl)phenyl isothiocyanate) and investigated the reaction of 18F-labeled oligonucleotide at 5′-position with a hexylamine linker [57]. The mentioned precursors (1–8) in Figure 8 have been prepared by following the procedure described in the literature [55,57,58,59]. Isothiocyanates containing leaving groups, such as bromide, iodide, and tosyl, were used as substrates in nucleophilic substitution reactions with [18F]fluoride to produce compound 8 (Figure 8) [57].
Oligonucleotides can be radiolabeled at 5′-position using ([18F]fluoromethyl)phenyl isothiocyanate, as shown in Figure 9. In 2003, de Vries et al. reported the 18F-radiolabeling of ASON using different alkylating agents, and N–(4-[18F]fluorobenzyl)–2-bromoacetamide α–bromo–α’–[18F]fluoro–m–xylene were found to be the most promising [56].

5.1.2. Labeling via Click Chemistry Using 1-(Azidomethyl)–4-(Fluoro–18F) Benzene

Another reported method for radiolabeling 18F to aptamers is through the click chemistry approach. Radiolabeling of an Sgc8 aptamer targeting PTK7 was performed using an alkynyl functionalized Sgc8 aptamer and 18F–benzylazide via click chemistry. The Sgc8 aptamer was modified at the 5′-end with a terminal hexynyl group and the automated radiochemical synthesis of 18F–fluorobenzyl azide was achieved using an aromatic fluoride substitution on a spirocyclic hypervalent iodine(III) precursor (Figure 10) [60,61].
The abovementioned click reaction protocol was applied for the PET imaging detection of HER2 in a mouse model with ovarian cancer in 2017 by 18F radiolabeling of a trivalent HER2-targeting aptamer and the alkyne-modified EGFR aptamer (ME07) via click chemistry by Cheng S. et al. in 2018 [62]. The 18F–benzyl azide precursor has recently indicated robust and reliable radiolabeling with high radiochemical yield [63,64].

5.1.3. Silicon-Based Chemistry for 18F-Radiolabeling

In this method, silylated oligonucleotide was utilized into the 18F-fluorination reaction (Figure 11). The silylated oligonucleotides were conjugated to different bifunctional silicon building blocks via click chemistry. Under physiological conditions, the di-tertbutylsilyl group is able to be substituted on the silicon atom to stabilize the SiF bond [65,66].

5.1.4. N–Succinimidyl 4-18F–Fluorobenzoate (18F–SFB)

In this method, 2,5-dioxopyrrolidin–1-yl 4-(fluoro–18F)benzoate (18F–SFB) as a precursor of 18F were used to react with a primary amine functionalized aptamer. In 2015, Jacobson et al. reported 18F-radiolabeling of a single-stranded DNA aptamer containing 70 nucleotides (Tenascin-C aptamer) using 18F–SFB. The aptamer was modified to have a 6-carbon chain and only one primary amine group at the 5′-position for conjugation purposes [67]. Radio-synthesis of 18F–SFB was performed in three automated steps using a 2-reaction-vial module. 18F–fluoride substitution on N,N,N–trimethyl–4-(2,3,4,5,6-pentamethylbenzyl)oxy)carbonyl)benzenaminium (I) was applied in the first reaction vial. The 4-(fluoro–18F)benzoic acid (18F–FBA) was obtained by hydrolysis reaction of 2,3,4,5,6-pentamethylbenzyl 4-(fluoro–18F)benzoate (II), followed by coupling with bis(2,5-dioxopyrrolidin–1-yl) carbonate and 4-(dimethylamino)pyridine in the second reaction vial to prepare 18F–SFB (Figure 12) [68]. The conjugation of 18F–SFB to an aptamer was performed in a basic sodium phosphate buffer (Figure 13), which resulted in a low but usable yield [67].

5.1.5. Hybridization-Based 18F-Radiolabeling of Aptamers:

Aptamers or aptamer-containing oligonucleotide sequences can be annealed to complementary sequences by following Watson and Crick base-pairing interactions. Park et al. in 2016 reported the development of the complementary oligonucleotide (cODN) hybridization-based aptamer conjugation approach for aptamer-based molecular imaging. The cODN was prelabeled with 18F and hybridized with a complementary sequence containing the AS1411 aptamer sequence in an aqueous condition. Briefly, the precursor PEG–mesylate was added to the 18F–KF–K222 complex and the mixture was stirred at 100 °C for 10 min. Isolated 18F–PEG–Azide (18F–FPA) was reacted with a mixture of 5′-alkyne modified oligonucleotide using N,N–diisopropylethylamine and copper (I) iodide in acetonitrile at 70 °C for 20 min. Then, a fully matched sequence (5′-CAG CCA CAC CAC CAG-3′) containing the nucleolin aptamer AS1411 sequence was hybridized in an annealing buffer by incubating the mixture at 95 °C for 5 min (Figure 14) [69].

5.2. 64Cu-Radiolabeling

64Cu (t1/2 = 12.7 h) displays both β-minus decay and positron emission and can be produced with highly specific activity using a medical cyclotron [70,71,72]. The half-life of this radionuclide enables centralized production and purification for research and clinical studies of targeting molecules, such as peptides and aptamers [73,74,75]. The optimal labeling with 64Cu can be achieved under physical conditions in which the oligonucleotides are stable. Based on the chemical properties, 64Cu is an attractive radionuclide for high-resolution, targeted aptamer-based PET imaging agents [76,77]. In order to radiolabel an aptamer with 64Cu, it must be linked to a chelator moiety, as shown in Figure 15 [78].
Rockey et al. used these different chelators to radiolabel a 5′-amine-modified (12 carbon linker) RNA aptamer that binds PSMA (prostate specific membrane antigen) on prostate cancer cells. Three conjugation strategies were reported: DOTA via the NHS ester, NOTA and PCTA via the 2-S-(4-Isothiocyanatobenzyl (p–SCN–Bn) linker group, and 1,8-Diamino-3,6,10,13,16,19-hexaazabicyclo[6,6,6]-eicosane(diAmSar)via a disuccinimidyl suberate (DSS) linker [78]. Paudyal et al. designed and synthesized a radionuclide–chelator–peptide nucleic acid for detecting HER2 (Human Epidermal Growth Factor Receptor 2) mRNA in malignant breast cancer by PET imaging (Figure 16) [79]. Junling Li et al. reported the labeling of AS1411 (a 26-base guanine-rich oligonucleotide aptamer) with 64Cu for micro PET/CT study by conjugating four different chelators [80].

5.3. Zirconium-89 Labeling

5.3.1. Desferrioxamine B Chelating Agent

Zirconium-89 (89Zr) is a positron emitter with a favorable half-life of 78.1 h, compared to other β-emitters, which allows long-term PET imaging. Because of its adequate half-life and positron emission, 89Zris used to radiolabel biomolecules for research in human and animal PET imaging, but it has not yet been approved for clinical applications [4]. Although direct labeling methods without using a chelator have been illustrated for 89Zr-introduction into serum proteins and liposomes, using an appropriate chelator system is a reasonable labeling approach for 89Zr [81,82]. 89Zr has not shown stable binding to DTPA [83], although it represents a higher stability than the comparable EDTA complex [84]. 89Zr complexation with Desferrioxamine B (a chelating agent exhibiting superior attributes compared to DTPA [83]) is still often used as a chelator for 89Zr-radiolabeling and is linked to the biomolecule before performing the radiolabeling reaction. The three hydroxamates and two additional anions or water molecules stabilize the Zr4+ ion, through the generation of an octadentate structural complex in the desferrioxamine B complex (Figure 17) [85].

5.3.2. Hyperbranched Polymers (HBPs)

Hyperbranched polymers (HBPs) are the targeted molecular imaging probes, which incorporate both targeting and molecular imaging modalities within one structure [86,87,88]. Because of their several unique properties, such as tunable solution behavior, critical phase behavior, and presence of large numbers of functional end groups, HBPs are a highly interesting nanocarrier for drug delivery and molecular imaging. The chemical synthesis of different types of branched polymers is reported in the literature [89]. In 2016, Fletcher et al. reported the attachment of an oligonucleotide aptamer with HBPs targeting VEGF (the vascular endothelial growth factors) (VEGF), which are upregulated in triple-negative breast cancer. The attachment of an aptamer to polymer chain was performed by copper-free azide–alkyne 1,3-dipolar cycloaddition. The aptamer–HBP complex was then functionalized with a 89Zr chelator (desferoxamine) to enable PET imaging with 89Zr (Figure 18) [90].

5.4. Gallium-68 (68Ga) Radiolabeling

Germanium-68 (68Ge) (t1/2 = 270.8 days) decays to 68Ga and 68Ga (t1/2 = 68 min) disintegrates by positron emission, which is used in PET imaging. Owing to the approximate half-life duration difference, the Germanium-68/Gallium-68 generator is manufactured in cyclotron and commercially available in nuclear medicine centers. The 68Ge/68Ga generator is approved in Europe for clinical use, particularly for the preparation of 68Ga–DOTATOC (TOC = a peptide like Tyr3–octreotide) and 68Ga–DOTATATE (TATE = Tyr3–octreotate) for neuroendocrine tumor detections [4]. In addition, 68Ga is considered as an attractive theranostic radionuclide because of its ability to be substituted by therapeutic radionuclides, such as 90Y or 177Lu [91]. Generator accessibility, simple and rapid labeling, and kit formulations are the advantages of 68Ga over 18F, the leading radionuclide for PET imaging [92]. 68Ga radiolabeling can be performed by complexation of 68Ga3+ cation by a potent chelator. Owing to commercial availability and well-characterized coordination chemistry, DOTA is the gold standard for 68Ga radiolabeling. Gallium (III) complex of NOTA ((1,4,7-triazanonane–1,4,7-triyl)triacetic acid) is thermodynamically more stable than DOTA and radiolabeling of NOTA can be achieved at room temperature under mild conditions compatible with most biomolecules [93]. Gijs M et al. in 2016 reported the 68Ga-radiolebelled HER2 aptamers [88]. A HER2-non-specific DNA oligonucleotide (5′-CCC TTT TAC ACA ACC ATC GAC ATA ACT AAA ACC ACC ACT G-3′), which was functionalized at its 5′-end with hexyldisulfide or hexylamine, was conjugated with p–SCN–Bn–NOTA (Figure 19 and Figure 20) at room temperature in the dark. Aptamers with disulfide functional groups were conjugated at inert atmosphere (argon) to avoid reoxidation in air. The main advantage of these bioconjugation approaches is that there is only one binding site for the chelator [94].
68Ga-radiolabeling of bioconjugate (solubilized in sodium acetate or a (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) HEPES buffer) was performed by addition of pre-concentrated 68Ga3+ eluate and incubation at room temperature. The author has pointed the low accessibility of primary amine group by three-dimensional structure of oligonucleotide as the reason for the low bioconjugation yields of the mentioned conjugation, as shown in Figure 19. Unlike amine–isothiocyanate-based reactions, the thiol–maleimide-based reaction is not reversible, so that the reducing agents are not be able to cleave the bond. The radiolabeling process of oligonucleotides should be conducted in nearly neutral pH circumstances to prevent acid-catalyzed depurination or hydrolysis incidents. Meanwhile, 68Ga3+ is stable only under acidic (pH < 3) conditions. 68Ga3+ creates insoluble Ga(OH)3 (gallium hydroxide) complexes at pH between 3 and 7, owing to strong affinity for hydroxide anions [95]. Radiolabeling of conjugated HER2 aptamer was performed using a lyophilized aptamer in a HEPES buffer and incubated for at least 5 min at room temperature (Figure 21) [96]. In 2015, Kang et al. reported 68Ga labeling of uMUC-1 (underglycosylated mucin-1, an early marker of tumor development) targeting an aptamer using a p–SCN–bn–NOTA chelating agent [97].

6. Conclusions and Future Prospects

Nucleic acid aptamers show high binding affinity to molecular targets with high specificity, which makes them effective biomolecules for generating excellent molecular imaging agents. They require functionalization to generate target-specific molecular imaging probes [98]. One of the most popular probe design approaches is the incorporation of functional groups at the 5′ or 3′ ends of aptamers, such as thiols or amines, via phosphoramidite reaction during aptamer synthesis [99]. Despite their many advantages as targeting agents, aptamers possess susceptibility to endogenous nuclease degradation in vivo, and common strategies to overcome this limitation are to enhance nuclease stability by the incorporation of non-natural nucleic acids, such as locked nucleic acids [100,101,102].
Molecular imaging by aptamers in nuclear tomographic imaging usually requires the covalent attachment of a chelator to the 5′ terminal amine of an oligonucleotide aptamer, and then the chelators conjugate radionuclides and it is feasible to proceed with nuclear imaging of the molecular target [98]. In this review, we highlight the most frequently utilized chelators and radionuclides in recent years for generating molecular imaging probes of aptamers, such as SPECT and PET imaging agents used in recent years have been highlighted. In general, aptamer functionalization may compromise its target affinity. However, in line with the reported literature discussed in this review, it is worth mentioning that radiolabeling of aptamers did not affect the actual aptamer target binding affinity. The literature indicates an enhancement of aptamer-targeted SPECT and PET probes and the recent promising results obtained in aptamer-targeted nuclear imaging probes will soon proceed to clinical applications, particularly in the oncology field.

Author Contributions

L.H.; writing—original draft preparation, visualization, editing, S.C.; review and editing, R.N.V.; visualization, editing & supervision.

Funding

This research was funded by Perron Institute for Neurological and Translational Science.

Acknowledgments

R.N.V. greatly acknowledges financial support from McCusker Charitable Foundation and the Perron Institute for Neurological and Translational Science. S.C. thanks the Scholarship support from Murdoch University and Perron Institute for Neurological and Translational Science.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Luker, G.D.; Piwnica-Worms, D. Molecular imaging in vivo with PET and SPECT. Acad. Radiol. 2001, 8, 4–14. [Google Scholar] [CrossRef]
  2. Pimlott, S.L.; Sutherland, A. Molecular tracers for the PET and SPECT imaging of disease. Chem. Soc. Rev. 2011, 40, 149–162. [Google Scholar] [CrossRef] [PubMed]
  3. Thorsten, D.; Viktor, G. Molecular imaging in oncology using positron emission tomography. Medicine 2018, 115, 175–181. [Google Scholar]
  4. Saha, G.B. Fundamentals of Nuclear Pharmacy, 7th ed.; Springer: Basel, Switzerland, 2018; pp. 53–55, 70, 88, 93, 111–112, 148. [Google Scholar]
  5. Aerts, A.; Nren, I.; Gijs, M. Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy. Curr. Pharm. Des. 2014, 20, 5218–5244. [Google Scholar] [CrossRef] [PubMed]
  6. Gijs, M.; Arets, A. Aptamers as radiopharmaceuticals for nuclear imaging and therapy. Nucl. Med. Biol. 2016, 43, 253–271. [Google Scholar] [CrossRef] [PubMed]
  7. Bruno, J.G.; Carrillo, M.P. Development, screening, and analysis of DNA aptamer libraries potentially useful for diagnosis and passive immunity of arboviruses. BMC Res. Notes 2012, 5, 633. [Google Scholar] [CrossRef] [PubMed]
  8. Bruno, J.G.; Kiel, J.L. In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. Biosens. Bioelectron. 1999, 14, 457–464. [Google Scholar] [CrossRef]
  9. Ciesiolka, J.; Gorski, J. Selection of an RNA domain that binds zn2+. RNA 1995, 1, 538–550. [Google Scholar] [PubMed]
  10. Shangguan, D.; Li, Y. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 2006, 103, 11838–11843. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Famulok, M. Molecular recognition of amino acids byRNA-aptamers: An l-citrulline binding RNA motif and its evolution into an l-arginine binder. J. Am. Chem. Soc. 1994, 116, 1698–1706. [Google Scholar] [CrossRef]
  12. Geiger, A.; Burgstaller, P. RNA aptamers that bind l-arginine with sub-micromolar dissociation constants and high enantioselectivity. Nucleic Acids Res. 1996, 24, 1029–1036. [Google Scholar] [CrossRef] [PubMed]
  13. Jenison, R.D.; Gill, S.C. High-resolution molecular discrimination by RNA. Science 1994, 263, 1425–1429. [Google Scholar] [CrossRef] [PubMed]
  14. Sassanfar, M.; Szostak, J.W. An RNA motif that binds ATP. Nature 1993, 364, 550–553. [Google Scholar] [CrossRef] [PubMed]
  15. Famulok, M.; Hartig, J.S. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem. Rev. 2007, 107, 3715–3743. [Google Scholar] [CrossRef] [PubMed]
  16. Wang, R.E.; Wu, H.E. Improving the stability of aptamers by chemical modification. Curr. Med. Chem. 2011, 18, 4126–4138. [Google Scholar] [CrossRef] [PubMed]
  17. Lipi, F.; Chen, S. In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies. RNA Biol. 2016, 13, 1232–1245. [Google Scholar] [CrossRef] [PubMed]
  18. Pang, X.; Cui, C. Bioapplications of cell-selex-generated aptamers in cancer diagnostics, therapeutics, theranostics and biomarker discovery: A comprehensive review. Cancers 2018, 10, 47. [Google Scholar] [CrossRef] [PubMed]
  19. Yoon, S.; Rossi, J. Targeted molecular imaging using aptamers in cancer. Pharmaceuticals 2018, 11, 71. [Google Scholar] [CrossRef] [PubMed]
  20. Lee, Y.S. Radiopharmaceuticals for molecular imaging. Open Nucl. Med. J. 2010, 2, 178–185. [Google Scholar] [CrossRef]
  21. Eszter Borbas, K.B.; Catia, S.M.F. Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-muc1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug. Chem. 2007, 18, 1205–1212. [Google Scholar] [CrossRef] [PubMed]
  22. Barros, A.L.B.; Andrade, S.F. Radiolabeling of low molecular weight d-galactose-based glycodendrimer with technetium-99m and biodistribution studies. J. Radioanal. Nucl. Chem. 2013, 298, 605–609. [Google Scholar] [CrossRef]
  23. Cristiane, R.C.; Barros, A.L. Aptamers directly radiolabeled with technetium-99m as a potential agent capable of identifying carcinoembryonic antigen (CEA) in tumor cells T84. Bioorg. Med. Chem. Lett. 2014, 24, 1998–2001. [Google Scholar]
  24. Sousa, L.; Camila, M. (1→3)-β-d-glucan aptamers labeled with technetium-99 m: Biodistribution and imaging in experimental models of bacterial and fungal infection. Nucl. Med. Biol. 2017, 46, 19–24. [Google Scholar]
  25. Santos, S.R.; Rodrigues, C. Identification of staphylococcus aureus infection by aptamers directly radiolabeled with technetium-99m. Nucl. Med. Biol. 2015, 42, 292–298. [Google Scholar] [CrossRef] [PubMed]
  26. Wu, X.; Liang, H. Cell-selex aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo. PLoS ONE 2014, 9, e90752. [Google Scholar] [CrossRef] [PubMed]
  27. Yuxia, L.; Guozheng, L. A brief review of chelators for radiolabeling oligomers. Materials 2010, 3, 3204–3217. [Google Scholar]
  28. Wang, Y.; Liu, G. Methods for MAG3 conjugation and 99mTc radiolabeling of biomolecules. Nat. Protoc. 2006, 1, 1477. [Google Scholar] [CrossRef] [PubMed]
  29. Abram, U.; Alberto, R. Technetium and rhenium: Coordination chemistry and nuclear medical applications. J. Braz. Chem. Soc. 2006, 17, 1486–1500. [Google Scholar] [CrossRef]
  30. Bormans, G.; Cleynhens, B. Comparison of benzyl, benzoyl and benzamidomethyl as protective groups for mercaptoacetyltriglycine (MAG3). J. Label. Compd. Radiopharm. 1989, 26, 50–52. [Google Scholar] [CrossRef]
  31. Winnard, P., Jr.; Chang, F. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl. Med. Biol. 1997, 24, 425–432. [Google Scholar] [CrossRef]
  32. Duncan, R.J.; Weston, P.D. A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. Anal. Biochem. 1983, 132, 68–73. [Google Scholar] [CrossRef]
  33. Liu, G.; Zhang, S. Improving the labeling of s-acetyl NHS−MAG3-conjugated morpholino oligomers. Bioconjug. Chem. 2002, 13, 893–897. [Google Scholar] [CrossRef] [PubMed]
  34. Rusckowski, M.; Qu, T. Inflammation and infection imaging with a (99m)Tc-neutrophil elastase inhibitor in monkeys. J. Nucl. Med. 2000, 41, 363–374. [Google Scholar] [PubMed]
  35. Yu-Min, Z.; Ning, L. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur. J. Nucl. Med. 2000, 27, 1700–1707. [Google Scholar]
  36. Kang, L.; Huo, Y. Noninvasive visualization of microRNA-155 in multiple kinds of tumors using a radiolabeled anti-miRNA oligonucleotide. Nucl. Med. Biol. 2016, 43, 171–178. [Google Scholar] [CrossRef] [PubMed]
  37. Kang, L.; Huo, Y. 99mTc radiolabeled anti-miR-155 oligonucleotide-phospholipids enveloped nanoparticles for cellular delivery and in vivo imaging. J. Nucl. Med. 2017, 58, 923. [Google Scholar]
  38. Liu, G.; Dou, S. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pre-targeting. Appl. Radiat. Isot. 2006, 64, 971–978. [Google Scholar] [CrossRef] [PubMed]
  39. Yan-Rong, Z.; Yong-Xue, Z. Uptake kinetics of 99mTc-MAG3-antisense oligonucleotide to PCNA and effect on gene expression in vascular smooth muscle cells. J. Nucl. Med. 2005, 46, 1052–1058. [Google Scholar]
  40. Gomes, S.D.R. 99mTc-MAG3-aptamer for imaging human tumors associated with high level of matrix metalloprotease-9. Bioconjug. Chem. 2012, 23, 2192–2200. [Google Scholar] [CrossRef] [PubMed]
  41. Kryza, D.; Debordeaux, F. Ex vivo and in vivo imaging and biodistribution of aptamers targeting the human matrix metalloprotease-9 in melanomas. PLoS ONE 2016, 11, e0149387. [Google Scholar] [CrossRef] [PubMed]
  42. Childs, R.; Hnatowich, D. Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m. J. Nucl. Med. 1985, 26, 293–299. [Google Scholar] [PubMed]
  43. Hnatowich, D.; Layne, W. Radioactive labeling of antibody: A simple and efficient method. Science 1983, 220, 613–615. [Google Scholar] [CrossRef] [PubMed]
  44. Eckelman, W.C.; Karesh, S.M. New compounds: Fatty acid and long chain hydrocarbon derivatives containing a strong chelating agent. J. Pharm. Sci. 1975, 64, 704–706. [Google Scholar] [CrossRef] [PubMed]
  45. Liu, G.; Cheng, D. Replacing 99m Tc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation. Mol. Imaging Biol. 2009, 11, 303–307. [Google Scholar] [CrossRef] [PubMed]
  46. Hnatowich, D.J.; Winnard, P., Jr. Technetium-99m labeling of DNA oligonucleotides. J. Nucl. Med. 1995, 36, 2306–2314. [Google Scholar] [PubMed]
  47. Calzada, V.; Moreno, M. Development of new PTK7-targeting aptamer-fluorescent and-radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept. Bioorg. Med. Chem. 2017, 25, 1163–1171. [Google Scholar] [CrossRef] [PubMed]
  48. Noaparast, Z.; Hosseinimehr, S. Tumor targeting with a (99m)Tc-labeled as 1411 aptamer in prostate tumor cells. J. Drug Target. 2015, 23, 497–505. [Google Scholar] [CrossRef] [PubMed]
  49. Schlesinger, J.; Fischer, C. Radiosynthesis of new [90y]-DOTA-based maleimide reagents suitable for the prelabeling of thiol-bearing l-oligonucleotides and peptides. Bioconjug. Chem. 2009, 20, 1340–1348. [Google Scholar] [CrossRef] [PubMed]
  50. Theobald, T. Sampson’s Textbook of Radiopharmacy; Pharmaceutical Press: London, UK, 2011; p. 96. [Google Scholar]
  51. Ren, B.X.; Yang, F. Magnetic resonance tumor targeting imaging using gadolinium labeled human telomerase reverse transcriptase antisense probes. Cancer Sci. 2012, 103, 1434–1439. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Bartlett, D.W.; Su, H. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 2007, 104, 15549–15554. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Lee, H.Y.; Li, Z. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med. 2008, 49, 1371–1379. [Google Scholar] [CrossRef] [PubMed]
  54. Sicco, E.; Baez, J. Derivatizations of sgc8-c aptamer to prepare metallic radiopharmaceuticals as imaging diagnostic agents: Syntheses, isolations, and physicochemical characterizations. Chem. Biol. Drug Des. 2018, 91, 747–755. [Google Scholar] [CrossRef] [PubMed]
  55. Nunn, A.D. Radiopharmaceuticals: Chemistry and Pharmacology; CRC Press: Boca raton, FL, USA, 1992; Volume 55. [Google Scholar]
  56. de Vries, E.F.; Vroegh, J. Evaluation of fluorine-18-labeled alkylating agents as potential synthons for the labeling of oligonucleotides. Appl. Radiat. Isot. 2003, 58, 469–476. [Google Scholar] [CrossRef]
  57. Elisabeth, H.C.; Léngstroma’b, B. Synthesis of 4-([18f] fluoromethyl) phenyl isothiocyanate and its use in labelling oligonucleotides. Acta Chem. Scand. 1997, 51, 1236–1240. [Google Scholar]
  58. Gonda, J.; Kristian, P. Some nucleophilic reactions of 2-isothiocyanatobenzyl bromide. A new simple synthesis of 2-substituted 4H-benzo [d][1,3] thiazines. Collect. Czech. Chem. Commun. 1986, 51, 2802–2809. [Google Scholar] [CrossRef]
  59. Litak, P.T.; Kauffman, J.M. Syntheses of reactive fluorescent stains derived from 5 (2)-aryl-2 (5)-(4-pyridyl) oxazoles and bifunctionally reactive linkers. J. Hetrocycl. Chem. 1994, 31, 457–479. [Google Scholar] [CrossRef]
  60. Rotstein, B.H.; Stephenson, N.A.; Vasdev, N.; Liang, S.H. Spirocyclic hypervalent iodine (III)-mediated radiofluorination of non-activated and hindered aromatics. Nat. Commun. 2014, 5, 4365. [Google Scholar] [CrossRef] [PubMed]
  61. Orit Jacobson, I.D.W.; Lu Wang, Z.W. 18F-labeled single-stranded DNA aptamer for PET imaging of protein tyrosine kinase-7 expression. J. Nucl. Med. 2015, 56, 1780–1785. [Google Scholar] [CrossRef] [PubMed]
  62. Cheng, S.; Jacobson, O.; Zhu, G.; Chen, Z.; Liang, S.H.; Tian, R.; Yang, Z.; Niu, G.; Zhu, X.; Chen, X. PET imaging of EGFR expression using an (18)F-labeled RNA aptamer. Eur. J. Nucl. Med. Mol. Imaging 2018. [Google Scholar] [CrossRef]
  63. Zhu, G.; Zhang, H. Combinatorial screening of DNA aptamers for molecular imaging of HER2 in cancer. Bioconjug. Chem. 2017, 28, 1068–1075. [Google Scholar] [CrossRef] [PubMed]
  64. James, D.; Escudier, J.M. A ‘click chemistry’approach to the efficient synthesis of modified nucleosides and oligonucleotides for PET imaging. Tetrahedron Lett. 2010, 51, 1230–1232. [Google Scholar] [CrossRef]
  65. Lucas, R.; Zerrouki, R. A rapid efficient microwave-assisted synthesis of a 3′, 5′-pentathymidine by copper (I)-catalyzed [3 + 2] cycloaddition. Tetrahedron 2008, 64, 5467–5471. [Google Scholar] [CrossRef]
  66. Sommer, L.; Marans, N. A new reaction in organosilicon chemistry. J. Am. Chem. Soc. 1951, 73, 882. [Google Scholar] [CrossRef]
  67. Orit, J.; Xuefeng, Y. PET imaging of tenascin-c with a radiolabeled single-stranded DNA aptamer. J. Nucl. Med. 2015, 56, 616–621. [Google Scholar]
  68. Jacobson, O.; Weiss, I.D. PET of tumor CXCR4 expression with 4-18F-T140. J. Nucl. Med. 2010, 51, 1796–1804. [Google Scholar] [CrossRef] [PubMed]
  69. Park, J.Y.; Lee, T.S. Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imaging. Biomaterials 2016, 100, 143–151. [Google Scholar] [CrossRef] [PubMed]
  70. Anderson, C.J.; Ferdani, R. Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research. Cancer Biother. Radiopharm. 2009, 24, 379–393. [Google Scholar] [CrossRef] [PubMed]
  71. Anderson, C.J.; Wadas, T.J. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q. J. Nucl. Med. Mol. Imaging 2008, 52, 185–193. [Google Scholar] [PubMed]
  72. Bass, L.A.; Wang, M. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug. Chem. 2000, 11, 527–532. [Google Scholar] [CrossRef] [PubMed]
  73. Shokeen, M.; Anderson, C.J. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res. 2009, 42, 832–841. [Google Scholar] [CrossRef] [PubMed]
  74. Smith, S.V. Molecular imaging with copper-64. J. Inorg. Biochem. 2004, 98, 1874–1901. [Google Scholar] [CrossRef] [PubMed]
  75. Sun, X.; Wuest, M. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J. Med. Chem. 2002, 45, 469–477. [Google Scholar] [CrossRef] [PubMed]
  76. Cai, H.; Li, Z. Evaluation of copper-64 labeled ambasar conjugated cyclic RGD peptide for improved microPET imaging of integrin αvβ3 expression. Bioconjug. Chem. 2010, 21, 1417–1424. [Google Scholar] [CrossRef] [PubMed]
  77. Ferreira, C.L.; Yapp, D.T. Comparison of bifunctional chelates for 64cu antibody imaging. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 2117–2126. [Google Scholar] [CrossRef] [PubMed]
  78. William, M.; Rockey, B. Synthesis and radiolabeling of chelator–RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg. Med. Chem. 2011, 19, 4080–4090. [Google Scholar] [Green Version]
  79. Paudyal, B.; Zhang, K. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Nucl. Med. Biol. 2013, 40, 994–999. [Google Scholar] [CrossRef] [PubMed]
  80. Li, J.; Zheng, H. Aptamer imaging with cu-64 labeled as 1411: Preliminary assessment in lung cancer. Nucl. Med. Biol. 2014, 41, 179–185. [Google Scholar] [CrossRef] [PubMed]
  81. Abou, D.S.; Thorek, D.L. 89zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer. Pharm. Res. 2013, 30, 878–888. [Google Scholar] [CrossRef] [PubMed]
  82. Meijs, W.E.; Haisma, H.J. A facile method for the labeling of proteins with zirconium isotopes. Nucl. Med. Biol. 1996, 23, 439–448. [Google Scholar] [CrossRef] [Green Version]
  83. Meijs, W.E.; Herscheid, J.D. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with zr-89. Int. J. Rad. Appl. Instrum. A 1992, 43, 1443–1447. [Google Scholar] [CrossRef]
  84. Wadas, T.J.; Wong, E.H. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for pet and spect imaging of disease. Chem. Rev. 2010, 110, 2858–2902. [Google Scholar] [CrossRef] [PubMed]
  85. Baroncelli, F.; Grossi, G. The complexing power of hydroxamic acids and its effect on the behaviour of organic extractants in the reprocessing of irradiated fuels—I. J. Inorg. Nucl. Chem. 1965, 27, 1085–1092. [Google Scholar] [CrossRef]
  86. Fuchs, A.V.; Tse, B.W. Evaluation of polymeric nanomedicines targeted to psma: Effect of ligand on targeting efficiency. Biomacromolecules 2015, 16, 3235–3247. [Google Scholar] [CrossRef] [PubMed]
  87. Pearce, A.K.; Rolfe, B.E. Development of a polymer theranostic for prostate cancer. Polym. Chem. 2014, 5, 6932–6942. [Google Scholar] [CrossRef]
  88. Rolfe, B.E.; Blakey, I. Multimodal polymer nanoparticles with combined 19F magnetic resonance and optical detection for tunable, targeted, multimodal imaging in vivo. J. Am. Chem. Soc. 2014, 136, 2413–2419. [Google Scholar] [CrossRef] [PubMed]
  89. England, R.M.; Rimmer, S. Hyper/highly-branched polymers by radical polymerisations. Polym. Chem. 2010, 1, 1533–1544. [Google Scholar] [CrossRef]
  90. Fletcher, N.L.; Houston, Z.H.; Simpson, J.D.; Veedu, R.N.; Thurecht, K.J. Designed multifunctional polymeric nanomedicines: Long-term biodistribution and tumour accumulation of aptamer-targeted nanomaterials. Chem. Commun. 2018. [Google Scholar] [CrossRef] [PubMed]
  91. Hörsch, D.; Ezziddin, S. Peptide receptor radionuclide therapy for neuroendocrine tumors in germany: First results of a multi-institutional cancer registry. In Theranostics, Gallium-68, and Other Radionuclides; Baum, R., Rösch, F., Eds.; Springer: Berlin, Heidelberg, 2013; pp. 457–465. [Google Scholar]
  92. Zeglis, B.M.; Lewis, J.S. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans. 2011, 40, 6168–6195. [Google Scholar] [CrossRef] [PubMed]
  93. Price, E.W.; Orvig, C. Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 2014, 43, 260–290. [Google Scholar] [CrossRef] [PubMed]
  94. Gijs, M.; Dammicco, S. Gallium-68-labelled NOTA-oligonucleotides: An optimized method for their preparation. J. Label. Compd. Radiopharm. 2016, 59, 63–71. [Google Scholar] [CrossRef] [PubMed]
  95. Baes, C.F.; Mesmer, R.S. The Hydrolysis of Cations; John Wiley & Sons: Hoboken, NJ, USA, 1976; pp. 318–319. [Google Scholar]
  96. Gijs, M.; Becker, G. Biodistribution of novel 68Ga-radiolabelled HER2 aptamers in mice. J. Nucl. Med. Radiat. Ther. 2016, 7, 300. [Google Scholar] [CrossRef]
  97. Kang, W.J.; Lee, J. Multimodal imaging probe for targeting cancer cells using umuc-1 aptamer. Colloids Surf. B Biointerfaces 2015, 136, 134–140. [Google Scholar] [CrossRef] [PubMed]
  98. Veedu, R.N. Aptamers: Tools for Nanotherapy and Molecular Imaging; CRC Press: Boca raton, FL, USA, 2017; pp. 1–363. [Google Scholar]
  99. Kalia, J.; Raines, R.T. Advances in bioconjugation. Curr. Org. Chem. 2010, 14, 138–147. [Google Scholar] [CrossRef] [PubMed]
  100. Lee, K.Y.; Kang, H. Bioimaging of nucleolin aptamer-containing 5-(n-benzylcarboxyamide)-2′-deoxyuridine more capable of specific binding to targets in cancer cells. J. Biomed. Biotech. 2010. [Google Scholar] [CrossRef] [PubMed]
  101. Li, W.; Yang, X. Real-time imaging of protein internalization using aptamer conjugates. Anal. Chem. 2008, 80, 5002–5008. [Google Scholar] [CrossRef] [PubMed]
  102. Shi, H.; He, X. Locked nucleic acid/DNA chimeric aptamer probe for tumor diagnosis with improved serum stability and extended imaging window in vivo. Anal. Chim. Acta 2014, 812, 138–144. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 11 00106 g001 550
Figure 1. Schematic presentation of aptamer-based therapeutic and/or diagnostic (theranostic) platform technology for targeted therapy and molecular imaging applications.
Figure 1. Schematic presentation of aptamer-based therapeutic and/or diagnostic (theranostic) platform technology for targeted therapy and molecular imaging applications.
Pharmaceuticals 11 00106 g001
Pharmaceuticals 11 00106 g002 550
Figure 2. Examples of chemically-modified nucleotides used to improve aptamer stability and kinetics.
Figure 2. Examples of chemically-modified nucleotides used to improve aptamer stability and kinetics.
Pharmaceuticals 11 00106 g002
Pharmaceuticals 11 00106 g003 550
Figure 3. 99mTc radiolabeling of S-benzoyl Mercaptoacetyltriglycine (MAG3) chelator.
Figure 3. 99mTc radiolabeling of S-benzoyl Mercaptoacetyltriglycine (MAG3) chelator.
Pharmaceuticals 11 00106 g003
Pharmaceuticals 11 00106 g004 550
Figure 4. Conjugation of the NHS–MAG3 chelator to an amine-derivatized aptamer, and radiolabeling.
Figure 4. Conjugation of the NHS–MAG3 chelator to an amine-derivatized aptamer, and radiolabeling.
Pharmaceuticals 11 00106 g004
Pharmaceuticals 11 00106 g005 550
Figure 5. Conjugation of the diethylenetriaminepentaacetic acid (DTPA) anhydride to an amine-derivatized aptamer, and radiolabeling.
Figure 5. Conjugation of the diethylenetriaminepentaacetic acid (DTPA) anhydride to an amine-derivatized aptamer, and radiolabeling.
Pharmaceuticals 11 00106 g005
Pharmaceuticals 11 00106 g006 550
Figure 6. Conjugation of the 6-hydrazinonicotinamide succinimidyl ester (Suc−HYNIC) to an amine-derivatized aptamer, and radiolabeling.
Figure 6. Conjugation of the 6-hydrazinonicotinamide succinimidyl ester (Suc−HYNIC) to an amine-derivatized aptamer, and radiolabeling.
Pharmaceuticals 11 00106 g006
Pharmaceuticals 11 00106 g007 550
Figure 7. Conjugation of the Tetraazacyclododecane tetraacetic acid (DOTA)–NHS–ester to amine-functionalized oligonucleotide for 99mTc radiolabeling.
Figure 7. Conjugation of the Tetraazacyclododecane tetraacetic acid (DOTA)–NHS–ester to amine-functionalized oligonucleotide for 99mTc radiolabeling.
Pharmaceuticals 11 00106 g007
Pharmaceuticals 11 00106 g008 550
Figure 8. Synthesis of (fluoro–18F) ethane isothiocyanatobenzene by various substrates (1–8).
Figure 8. Synthesis of (fluoro–18F) ethane isothiocyanatobenzene by various substrates (1–8).
Pharmaceuticals 11 00106 g008
Pharmaceuticals 11 00106 g009 550
Figure 9. Radiolabeling of 5′-position modified oligonucleotide by ([18F]fluoromethyl)phenyl isothiocyanate.
Figure 9. Radiolabeling of 5′-position modified oligonucleotide by ([18F]fluoromethyl)phenyl isothiocyanate.
Pharmaceuticals 11 00106 g009
Pharmaceuticals 11 00106 g010 550
Figure 10. Conjugation of 1-(azidomethyl)–4-(fluoro–18F)benzene to a terminal hexynyl modified aptamer.
Figure 10. Conjugation of 1-(azidomethyl)–4-(fluoro–18F)benzene to a terminal hexynyl modified aptamer.
Pharmaceuticals 11 00106 g010
Pharmaceuticals 11 00106 g011 550
Figure 11. Conjugation of 18F by substitution of hydrogen atom on silylated oligonucleotide.
Figure 11. Conjugation of 18F by substitution of hydrogen atom on silylated oligonucleotide.
Pharmaceuticals 11 00106 g011
Pharmaceuticals 11 00106 g012 550
Figure 12. The 3 step synthesis of 2,5-dioxopyrrolidin–1-yl 4-(fluoro–18F)benzoate (18F–SFB).
Figure 12. The 3 step synthesis of 2,5-dioxopyrrolidin–1-yl 4-(fluoro–18F)benzoate (18F–SFB).
Pharmaceuticals 11 00106 g012
Pharmaceuticals 11 00106 g013 550
Figure 13. Conjugation of 18F–SFB to a Tenascin-C aptamer.
Figure 13. Conjugation of 18F–SFB to a Tenascin-C aptamer.
Pharmaceuticals 11 00106 g013
Pharmaceuticals 11 00106 g014 550
Figure 14. Schematic illustration of Hybridization-based 18F-Radiolabeling.
Figure 14. Schematic illustration of Hybridization-based 18F-Radiolabeling.
Pharmaceuticals 11 00106 g014
Pharmaceuticals 11 00106 g015 550
Figure 15. Chelator structures used to conjugate 64Cu to biomolecules.
Figure 15. Chelator structures used to conjugate 64Cu to biomolecules.
Pharmaceuticals 11 00106 g015
Pharmaceuticals 11 00106 g016 550
Figure 16. 64Cu-radiolabeling steps of peptide nucleic acid.
Figure 16. 64Cu-radiolabeling steps of peptide nucleic acid.
Pharmaceuticals 11 00106 g016
Pharmaceuticals 11 00106 g017 550
Figure 17. Conjugation of 89Zr to a Desferrioxamine B (DFO) bioconjugate.
Figure 17. Conjugation of 89Zr to a Desferrioxamine B (DFO) bioconjugate.
Pharmaceuticals 11 00106 g017
Pharmaceuticals 11 00106 g018 550
Figure 18. Oligonucleotide aptamer–hyperbranched polymer (HBP) conjugates as a targeted molecular imaging probe.
Figure 18. Oligonucleotide aptamer–hyperbranched polymer (HBP) conjugates as a targeted molecular imaging probe.
Pharmaceuticals 11 00106 g018
Pharmaceuticals 11 00106 g019 550
Figure 19. Amine–isothiocyanate bioconjugation reaction of isothiocyanate (SCN)–Bn–1,4,7-triazacyclononane–N,N′,N′′–triacetic acid (NOTA) to a hexylamine-functionalized oligonucleotide.
Figure 19. Amine–isothiocyanate bioconjugation reaction of isothiocyanate (SCN)–Bn–1,4,7-triazacyclononane–N,N′,N′′–triacetic acid (NOTA) to a hexylamine-functionalized oligonucleotide.
Pharmaceuticals 11 00106 g019
Pharmaceuticals 11 00106 g020 550
Figure 20. Thiol–maleimide bioconjugation reaction of maleimidoethylmonoamide(MMA)–NOTA to a hexylthiol-functionalized oligonucleotide.
Figure 20. Thiol–maleimide bioconjugation reaction of maleimidoethylmonoamide(MMA)–NOTA to a hexylthiol-functionalized oligonucleotide.
Pharmaceuticals 11 00106 g020
Pharmaceuticals 11 00106 g021 550
Figure 21. 68Ga-radiolabeling of Thiourea–NOTA–aptamer.
Figure 21. 68Ga-radiolabeling of Thiourea–NOTA–aptamer.
Pharmaceuticals 11 00106 g021
Table
Table 1. Characteristics of common nuclear medicine radionuclides [4,20].
Table 1. Characteristics of common nuclear medicine radionuclides [4,20].
RadioisotopesAtomic NumberPhysical Half-LifeDecay Mode (%)
11C620.4 minβ+(100)
13N79.96 minβ+(100)
15O82.03 minβ+(100)
18F9109.8 minβ+(97)
62Cu299.76 minβ+(97), EC(3)
64Cu2912.8 hβ+ Or β−, EC
67Ga313.3 daysEC(100)
68Ga3168 minβ+(89), EC(11)
82Rb3775 sβ+(95), EC(5)
89Zr4078.1 hβ+(23), EC(77)
94mTc4352 minβ+(72), EC(28)
99mTc436.0 hIT(100)
111In492.8 daysEC(100)
123I5313.2 hEC(100)
β+(Positron), EC (Electron Capture), IT (Isomeric Transition).

Share and Cite

MDPI and ACS Style

Hassanzadeh, L.; Chen, S.; Veedu, R.N. Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging. Pharmaceuticals 2018, 11, 106. https://doi.org/10.3390/ph11040106

AMA Style

Hassanzadeh L, Chen S, Veedu RN. Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging. Pharmaceuticals. 2018; 11(4):106. https://doi.org/10.3390/ph11040106

Chicago/Turabian Style

Hassanzadeh, Leila, Suxiang Chen, and Rakesh N. Veedu. 2018. "Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging" Pharmaceuticals 11, no. 4: 106. https://doi.org/10.3390/ph11040106

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop